A leading obesity drug is being suspended from use in the UK amid fears it increases the risk of heart attacks and strokes.
The Medicines and Healthcare Products Regulatory Agency has told doctors to stop prescribing sibutramine and review its use in patients already taking it.
The drug works by altering chemical messages to the brain which control cravings for food.
The regulator says it has been used by 86,000 people in the past year.
While it is a common obesity drug, the most popular, orlistat, a pill which prevents fat absorption, is much more widely used and is taken by hundreds of thousands of people each year.
